- Home
- ELVA vs FATE Comparison
ELVA vs FATE Comparison
Compare ELVA & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVA
- FATE
- Stock Information
- Founded
- ELVA 1996
- FATE 2007
- Country
- ELVA Canada
- FATE United States
- Employees
- ELVA N/A
- FATE N/A
- Industry
- ELVA
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ELVA
- FATE Health Care
- Exchange
- ELVA Nasdaq
- FATE Nasdaq
- Market Cap
- ELVA 91.8M
- FATE 108.2M
- IPO Year
- ELVA N/A
- FATE 2013
- Fundamental
- Price
- ELVA $2.53
- FATE $0.77
- Analyst Decision
- ELVA Strong Buy
- FATE Hold
- Analyst Count
- ELVA 5
- FATE 9
- Target Price
- ELVA $6.10
- FATE $5.50
- AVG Volume (30 Days)
- ELVA 67.3K
- FATE 1.6M
- Earning Date
- ELVA 05-12-2025
- FATE 03-05-2025
- Dividend Yield
- ELVA N/A
- FATE N/A
- EPS Growth
- ELVA N/A
- FATE N/A
- EPS
- ELVA N/A
- FATE N/A
- Revenue
- ELVA $43,693,000.00
- FATE $13,631,000.00
- Revenue This Year
- ELVA $55.23
- FATE N/A
- Revenue Next Year
- ELVA $63.75
- FATE N/A
- P/E Ratio
- ELVA N/A
- FATE N/A
- Revenue Growth
- ELVA N/A
- FATE N/A
- 52 Week Low
- ELVA $1.67
- FATE $0.74
- 52 Week High
- ELVA $3.58
- FATE $7.35
- Technical
- Relative Strength Index (RSI)
- ELVA 51.80
- FATE 33.08
- Support Level
- ELVA $2.30
- FATE $0.83
- Resistance Level
- ELVA $2.70
- FATE $0.96
- Average True Range (ATR)
- ELVA 0.17
- FATE 0.06
- MACD
- ELVA -0.01
- FATE -0.00
- Stochastic Oscillator
- ELVA 37.10
- FATE 11.54
About ELVA Electrovaya Inc.
Electrovaya Inc designs develop and manufacture proprietary lithium-ion batteries, battery systems, and battery-related products for energy storage, clean electric transportation and other specialized applications. It is a technology-focused company with extensive IP. The company generates revenue from the sale of batteries and battery systems. Business operations are segmented based on large format batteries and others. This technology offers enhanced safety and battery longevity. Geographically it earns key revenue from the United States.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.